Literature DB >> 16597815

Management of inflammatory bowel diseases in Eastern Europe.

L Lakatos1, P L Lakatos.   

Abstract

Limited data are available on the management of inflammatory bowel diseases (IBD) in East European countries. The diagnostic tools and most treatment options are also available in Eastern Europe. The diagnostic procedures commonly used became more sophisticated in the past few years, with a greater use of computed tomography/magnetic resonance imaging and serology testing; however, double contrast barium enema, enteroclysis, and endoscopy remained standard. The medical therapy and surgical strategies are also somewhat different from those applied in Western countries. In ulcerative colitis, besides mesalazine, the use of sulphasalazine is still frequent, while azathioprine is only used in a minority of patients. The use of conventional corticosteroids is common and the rate of non-colorectal cancer associated colectomies is low. In contrast, 5-aminosalicylates are still used for maintenance in Crohn's disease and azathioprine is generally less frequently given compared with Western Europe. Biological agents have also become available about five years ago, yet their use is restricted mainly to specialised centres.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16597815      PMCID: PMC2579633          DOI: 10.1136/pgmj.2005.043901

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  45 in total

Review 1.  [Laboratory values, endoscopy and new imaging. What is the status of diagnosis?].

Authors:  H Herfarth
Journal:  Internist (Berl)       Date:  2002-11       Impact factor: 0.743

2.  Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease.

Authors:  J A Eaden; J F Mayberry
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 3.  Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe?

Authors:  L Lakatos; P L Lakatos
Journal:  Postgrad Med J       Date:  2006-05       Impact factor: 2.401

Review 4.  Factors affecting recurrence after surgery for Crohn's disease.

Authors:  Takayuki Yamamoto
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

5.  Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel diseases.

Authors:  J Bartůnková; I Kolárová; A Sedivá; E Hölzelová
Journal:  Clin Immunol       Date:  2002-02       Impact factor: 3.969

6.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

7.  Impact of race and ethnicity on inflammatory bowel disease.

Authors:  Dhiman Basu; Ivelisse Lopez; Aparna Kulkarni; Joseph H Sellin
Journal:  Am J Gastroenterol       Date:  2005-10       Impact factor: 10.864

8.  [Initial experience with detection of Saccharomyces cerevisiae antibodies in patients with primary nonspecific inflammatory bowel disease].

Authors:  K Malícková; I Janatková; T Fucíková; S Adamec; M Lukás
Journal:  Epidemiol Mikrobiol Imunol       Date:  2001-08       Impact factor: 0.444

9.  Clinical value of technetium-99m-HMPAO-labeled leukocyte scintigraphy and spiral computed tomography in active Crohn's disease.

Authors:  T Molnár; M Papós; C Gyulai; E Ambrus; L Kardos; F Nagy; A Palkó; L Pávics; J Lonovics
Journal:  Am J Gastroenterol       Date:  2001-05       Impact factor: 10.864

10.  Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial.

Authors:  A Hillary Steinhart; Brian G Feagan; Cindy J Wong; Margaret Vandervoort; Shelley Mikolainis; Kenneth Croitoru; Ernest Seidman; Desmond J Leddin; Alain Bitton; Eric Drouin; Albert Cohen; Gordon R Greenberg
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

View more
  1 in total

1.  Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.

Authors:  Gyorgy Kovacs; Nora Sipeki; Boglarka Suga; Tamas Tornai; Kai Fechner; Gary L Norman; Zakera Shums; Peter Antal-Szalmas; Maria Papp
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.